OTC:SHPHY

Drug Registration Approval Granted for Sihuan Pharmaceutical's Pediatric Compound Amino Acid Injection (18AA-II)

HONG KONG, March 23, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that drug registration approval has been granted by the National Medical Products Administ...

2020-03-23 17:57 3225

Sihuan Pharmaceutical Announces Clinical Research of Favipiravir, Co-Developed with the Academy of Military Medical Sciences of the People's Liberation Army, Has Commenced

HONG KONG, March 2, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the clinical research of Favipiravir tablet, which was co-developed by the Group and t...

2020-03-02 14:15 5002

Sihuan Pharmaceutical Announces Acquisition of All Interests and Intellectual Property Rights of Plazomicin, A New Generation of Aminoglycoside Antibiotics in the Greater China Region

HONG KONG, Feb. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu (HK) Biopharmaceutical Limited (''Xuanzhu''), a wholly-owned subsidiary of the...

2020-02-20 18:59 11072

Sihuan Pharmaceutical: Production Approval Granted For Rivastigmine Hydrogen Tartrate Capsule, The First Drug Passing Consistency Evaluation And Levetiracetam Tablet And The First Registration Approval Granted For Midazolam Oromucosal Solution

HONG KONG, Feb. 18, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that rivastigmine hydrogen tartrate capsule and levetiracetam tablet developed by the Group...

2020-02-18 18:07 5821

Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases

HONG KONG, Feb. 14, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the progress achieved by the Group in the research and development of drugs for treati...

2020-02-14 10:35 6096

Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area

HONG KONG, Feb. 12, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group and Hetero Labs Limited ("Hetero"), a company registered under the laws ofI...

2020-02-12 05:00 5978

Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions

HONG KONG, June 10, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janaglif...

2019-06-10 16:28 6365

Sihuan Pharm Post-launching Large-scale Clinical Trials of Cinepazide Maleate Injection were Completed With Efficacy Verified

HONG KONG, June 1, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced that the Group has completed the post-launch clinical trials of "Cinepazide Maleate Inject...

2019-06-01 11:18 1409

Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809

HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by t...

2019-05-29 18:00 4478

Sihuan Pharm Becomes the First Chinese Company that was Granted Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Ceftazidime/Sodium Chloride Injection"

HONG KONG, May 27, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Group"), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the "non-PVC solid-liquid double chamber bag for ...

2019-05-27 17:08 4533

Sihuan Pharm's Innovative Digestive System Drug Anaprazole Sodium Achieved Early Completion of Patient Recruitment for Phase II Clinical Trial in China

HONG KONG, April 25, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced the early completion of patient recruitment for Phase II clinical trial inChina for Anaprazole...

2019-04-25 21:07 4090

Sihuan Pharmaceutical Meets all Conditions for Resumption of Trading

HONG KONG, Feb. 27, 2016 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) (the "Company", together with its subsidiaries, the "Group"), a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise inChina's prescription market, announced that the...

2016-02-27 00:49 3908

Sihuan Pharmaceutical Clarifies Misleading Media Reports On Application Status for Trading Resumption

HONG KONG, Nov. 2, 2015 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Group") has become aware of certain media reports stating the Group's application for resumption of trading has been "denied" or "rejected" by The Stock Exchange of Hong...

2015-11-02 21:50 2404